PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1684379
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1684379
Mammalian cell fermentation technology Market size was valued at US$ 50,789.43 Million in 2024, expanding at a CAGR of 8.99% from 2025 to 2032.
Mammalian cells are widely used for producing therapeutic proteins like vaccines, monoclonal antibodies, and other biologics, along with various source materials like Human Embryonic Kidney (HEK) cells, Chinese Hamster Ovary (CHO) cells, and others. The mammalian cell fermentation technology industry will likely see significant growth in the forecasted years due to several factors, such as the rising demand for biosimilars and biologics, the increasing prevalence of chronic diseases, and advancements in mammalian cell culture techniques.
Mammalian Cell Fermentation Technology Market- Market Dynamics
Increasing demand for biologics and biosimilars to propel market growth
The mammalian cell fermentation technology industry is witnessing a significant rise due to the rising demand for biosimilars and biologics. These treatments are important in managing various conditions, including infectious diseases, cancer, and autoimmune conditions. Additionally, mammalian cell fermentation technology keeps expanding as pharmaceutical firms invest more in the creation of novel biologics. However, a vital factor restraining the widespread use of this technology is the high expenses associated with its manufacturing process. Furthermore, the rise in chronic diseases like cancer, diabetes, and heart disease resulted in a growth in the mammalian cell fermentation technology market. There is an ongoing demand for mammalian cell fermentation technologies as many diseases need long-term treatment, often with biologics. As a result, the market for mammalian cell fermentation technology is projected to grow over the coming years owing to the constant demand for biosimilars and biologics along with the rise in chronic illnesses.
Mammalian Cell Fermentation Technology Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.99% over the forecast period (2025-2032)
Based on type segmentation, Chinese hamster ovary (CHO) cell fermentation was predicted to show maximum market share in the year 2024
Based on application segmentation, monoclonal antibodies was the leading application in 2024
Based on end-use segmentation, CMOs & CDMOs was the leading end-use in 2024
On the basis of region, North America was the leading revenue generator in 2024
The global mammalian cell fermentation technology market is segmented on the basis of type, application, end-use, and region.
The market is divided into five categories based on type: baby hamster kidney (BHK) cell fermentation, chinese hamster ovary (CHO) cell fermentation, human embryonic kidney (HEK) Cell fermentation, murine myeloma cell fermentation, and others. The Chinese hamster ovary (CHO) cell fermentation sector is expected to dominate the market. CHO cells have prompted immense attention because of their ability to efficiently manufacture complex therapeutic proteins. Additionally, the rise in demand can be attributed to various factors such as the optimization of culture media and conditions, advancements in genetic engineering techniques for enhancing cell line development, and a robust regulatory environment.
The market is divided into six categories based on application: enzymes, hormones, monoclonal antibodies, recombinant proteins, vaccines, others. The monoclonal antibodies segment is likely to hold the highest market share as high adoption can be attributed to the crucial role that antibodies play in diagnostic and therapeutic applications, leading to growing demand for robust production methods. In addition, advancements in cell line development, bioreactor technologies, and bioprocessing techniques, leading to better product quality, higher yields, and efficient production processes, have fueled the segment's explosive expansion. Likewise, the need for precisely targeted therapies and the increasing prevalence of chronic diseases have also fueled the demand for mammalian antibodies.
The market is divided into three categories based on end-use: academic & research institutes, biopharmaceutical companies, and CMOs & CDMOs. The CMOs & CDMOs sector is likely to maintain its dominance during the forecast period due to the complex manufacturing techniques that CDMOs and CMOs specialize in. These organizations provide a simplified and affordable solution for businesses aiming to outsource their manufacturing processes, allowing them to concentrate on development and research. Moreover, quality standards and regulatory requirements are more stringent, thereby pharmaceutical businesses to collaborate with reputable CMOs and CDMOs that maintain the proficiency to comply with these demands.
Mammalian Cell Fermentation Technology Market- Geographical Insights
North America accounts for the largest share of the mammalian cell fermentation technology market. The market growth is attributed to the region's highly developed healthcare sector, favorable government regulations, and a strong presence of significant biopharmaceutical companies. Moreover, the rising demand for biologics and biosimilars and the rising incidence of chronic illnesses are attributed to driving the region's market growth.
The Asia Pacific region is likely to increase at a swift rate owing to the accessibility of trained staff at a reduced cost, the favorable regulatory environment, and rising investments by multinational corporations.
The market for fermenting mammalian cells is being driven by technological advancements in cell culture. The rising demand for mammalian cell fermentation technology for numerous applications has created various market possibilities for major players to capitalize on. These industry players primarily adopt several strategies that involve acquisitions, collaborations, partnerships, and mergers to establish a global footprint and maintain market competition. Moreover, the market's progress is fostered by the ongoing research and development efforts to enhance bioprocessing methods, along with the rising spending on biomanufacturing infrastructure. For instance, in January 2023, Fosun Pharmahas signed an exclusive license agreement with Shanghai Henlius Biotech, Inc. in the United States (US) for the commercialization of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab. This marks a significant turning point for Fosun Pharma's development in the US.
In July 2023, Lonza launched the TheraPRO(R) CHO Media System, an innovative cell culture platform that streamlines procedures and optimizes productivity and protein quality when utilized with GS-CHO cell lines. The launch of this technology supports biotechnology and pharmaceutical companies that manufacture therapeutic proteins to enhance product quality while streamlining time-to-market.